• 1
    Gabay C, Kushner I. Acute phase reactants and other systemic responses to inflammation. N Engl J Med 1999; 340: 44854.
  • 2
    Dearing WH, McGuckin WH, Elveback LR. Serum alpha1-acid glycoprotein in chronic ulcerative colitis. Gastroenterology 1969; 56: 295303.
  • 3
    Fagan EA, Dyck RF, Maton PN, et al. Serum levels of C-reactive protein in Crohn's disease and ulcerative colitis. Eur J Clin Invest 1982; 12: 35160.
  • 4
    Sachar DB, Smith H, Chan S, Cohen LB, Lichtiger S, Messer J. Erythrocytic sedimentation rate as a measure of clinical activity in inflammatory bowel disease. J Clin Gastroenterol 1986; 8: 64750.
  • 5
    Sachar DB, Luppescu NE, Bodian C, Shlien RD, Fabry TL, Gumaste VV. Erythrocyte sedimentation as a measure of Crohn's disease activity: opposite trends in ileitis versus colitis. J Clin Gastroenterol 1990; 12: 6436.
  • 6
    Andres C, Descos L, Landais P, et al. Assessment of appropriate laboratory measurements to supplement the Crohn's disease activity index. Gut 1981; 22: 5714.
  • 7
    Jensen KB, Jarnum S, Koudahl G, et al. Serum orosomucoid levels in ulcerative colitis. Its relation to clinical activity, protein loss, and turnover of albumin and IgG. Scand J Gastroenterol 1976; 11: 17793.
  • 8
    Vermeire S, Van Assche G, Rutgeerts P. C-reactive protein as a marker for inflammatory bowel disease. Inflamm Bowel Dis 2004; 10: 6615.
  • 9
    Solem CA, Loftus EV Jr, Tremaine WJ, Harmsen WS, Zinsmeister AR, Sandborn WJ. Correlation of C-reactive protein with clinical, endoscopic, histologic, and radiographic activity in inflammatory bowel disease. Inflamm Bowel Dis 2005; 11: 70712.
  • 10
    Saverymuttu SH, Hodgson HJ, Chadwick VS, et al. Differing acute phase responses in Crohn's disease and ulcerative colitis. Gut 1986; 27: 80913.
  • 11
    Hammer HB, Kvein TK, Glennas A, et al. A longitudinal study calprotectin as an inflammatory marker in patients with reactive arthritis. Clin Exp Rheumatol 1995; 13: 5964.
  • 12
    Florin TH, Paterson EW, Fowler EV, Radford-Smith GL. Clinically active Crohn's disease in presence of low C-reactive protein. Scand J Gastroenterol 2006; 41: 30611.
  • 13
    Boiliviant M, Leoni M, Tariciotti D, et al. The clinical significance of serum C reactive protein in Crohn's disease: result of a prospective longitudinal study. J Clin Gastroenterol 1988; 10: 4015.
  • 14
    Consigney Y, Modigliani R, Colombel JF, et al. Biologic markers of short-term relapse in Crohn's disease. Gastroenterology 2001; 20 (Suppl.): A53.
  • 15
    Wright JP, Young GO, Tigler-Wybrandi N. Predictores of acute relapse of Crohn's disease. A laboratory and clinical study. Dig Dis Sci 1987; 32: 16470.
  • 16
    Talstad I, Rootwelt K, Gjone E. Thrombocytosis in ulcerative colitis and Crohn's disease. Scand J Gastroenterol 1973; 8: 1358.
  • 17
    Philips MS. Dronfield MW. Platelet count in patients with Crohn's disease. Br Med J 1983; 286: 1895.
  • 18
    Prior C, Bollbach R, Fuchs D, et al. Urinary neopterin, a marker of clinical activity in patients with Crohn's disease. Clin Chim Acta 1986; 155: 1121.
  • 19
    Niederwieser D, Fuchs D, Hausen A, et al. Neopterin as a new biochemical marker in the clinical assessment of ulcerative colitis. Immunobiology 1985; 170: 3206.
  • 20
    Hyams JS, Treem WR, Eddy E, Wyzga N, Moore RE. Tumor necrosis factor-alpha is not elevated in children with inflammatory bowel disease. J Pediatr Gastroenterol Nutr 1991; 12: 2336.
  • 21
    Murch SH, Lamkin VA, Savage MO, Walker-Smith JA, MacDonald TT. Serum concentration of tumor necrosis factor alpha in childhood chronic inflammatory bowel disease. Gut 1991; 32: 9137.
  • 22
    Gardiner KR, Halliday MI, Barclay GR, et al. Significance of systemic endotoxaemia in inflammatory bowel disease. Gut 1995; 36: 897901.
  • 23
    Braegger CP, Nicholls S, Murch SH, et al. Tumour necrosis factor alpha in stool as a marker of intestinal inflammation. Lancet 1992; 339: 8991.
  • 24
    Saiki T, Mitsuyama K, Toyonaga A, et al. Detection of pro and anti-inflammatory cytokines in stools of patients with inflammatory bowel disease. Scand J Gastroenterol 1998; 33: 61622.
  • 25
    Stronkhorst A, Jansen J, Tytgat G, et al. Soluble IL-2 and TNF receptors p55 and p75 in Crohn's disease. Gastroenterology 1994; 106: A779.
  • 26
    Van Dullemen HM, Van Deventer SJ, Hommes DW, et al. Treatment of Creohn's disease with anti-tumor necrosis factor chimeric monoclonal antibody (cA2). Gastroenterology 1995; 105: 12935.
  • 27
    Propst A, Propst T, Herold M, et al. Interleukin-1 receptor antagonist in differential diagnosis of inflammatory bowel disease. Eur J Gastroenterol Hepatol 1995; 7: 10316.
  • 28
    Casini-Raggi V, Kam L, Chong YJT, et al. Mucosal imbalance of IL-1 and IL-1 receptor antagonist in inflammatory bowel disease. J Immunol 1995; 154: 243440.
  • 29
    Williams AJ, Symons JA, Watchet K, et al. Soluble interleukin-2 receptors and disease activity in Crohn's disease. J Autoimmun 1992; 5: 2519.
  • 30
    Nielsen OH, Brynsskov J. Soluble interleukin-2 receptors in ulcerative colitis. Mediators Inflamm 1993; 2: 1158.
  • 31
    Mahida YR, Kurlac L, Gallaghar A, et al. High circulating concentrations of interleukin-6 in active Crohn's disease but not ulcerative colitis. Gut 1992; 32: 15314.
  • 32
    Gustot T, Lemmers A, Louis E, et al. Profile of soluble cytokine receptors in Crohn's disease. Gut 2005; 54: 48895.
  • 33
    Jones SC, Evans SW, Lobo AJ, Cesca M, Axon AT, Whicher JT. Serum Interleukin-8 in inflammatory bowel disease. J Gastroenterol Hepatol 1993; 8: 50812.
  • 34
    Kucharzik T, Stoll R, Lugering N, Domschke W. Circulating antiinflammatory cytokine IL-10 in patients with inflammatory bowel disease (IBD). Clin Exp Immunol 1995; 100: 4526.
  • 35
    Kader HA, Tchernev VT, Satyaraj E, et al. Protein microarray analysis of disease activity in pediatric inflammatory bowel disease demonstrates elevated serum PLGF, IL-7, TGF-beta1, and IL-12p40 levels in Crohn's disease and ulcerative colitis patients in remission versus active disease. Am J Gastroenterol 2005; 100: 41423.
    Direct Link:
  • 36
    Stallmach A, Giese T, Schmidt C, Ludwig B, Mueller-Molaian I, Meuer SC. Cytokine/chemokine transcript profiles reflect mucosal inflammation in Crohn's disease. Int J Colorectal Dis 2004; 19: 30815.
  • 37
    Schmidt C, Giese T, Ludwig B, et al. A expression of interleukin-12-related cytokine transcripts in inflammatory bowel disease: elevated interleukin-23p19 and interleukin-27p28 in Crohn's disease but not in ulcerative colitis. Inflamm Bowel Dis 2005; 11: 1623.
  • 38
    Tsukada Y, Nakamura T, Iimura M, Iizuka BE, Hayashi N. Cytokine profile in colonic mucosa of ulcerative colitis correlates with disease activity and response to granulocytapheresis. Am J Gastroenterol 2002; 97: 28208.
    Direct Link:
  • 39
    Silva MA, Menezes J, Deslandres C, Seidman EG. Anti-inflammatory role of interleukin-15 in Crohn's disease. Inflamm Bowel Dis 2005; 11: 21930.
  • 40
    Goggins MG, Goh J, O'Connell MA, Weir DG, Kelleher D, Mahmud N. Soluble adhesion molecules in inflammatory bowel disease. Ir J Med Sci 2001; 170: 10711.
  • 41
    Assche GV, Rutgeerts P. Physiological basis for novel drug therapies used to treat the inflammatory bowel disease: I. Immunology and therapeutic potential of antiadhesion molecule therapy in inflammatory bowel disease. Am J Physiol Gastrointest Liver Physiol 2005; 288: 16974.
  • 42
    Magro F, Araujo F, Pereira P, Meireles E, Diniz-Ribeiro M, Velosom FT. Soluble selectins, sICAM, sVCAM, and angiogenic proteins in different activity groups of patients with inflammatory bowel disease. Dig Dis Sci 2004; 49: 126574.
  • 43
    Riedl S, Tandara A, Reinshagen M, et al. Serum tenascin-C is an indicator of inflammatory bowel disease activity. Int J Colorectal Dis 2001; 16: 28591.
  • 44
    Zissis M, Afroudakis A, Galanopoulos G, et al. B2 microglobulin: is it a reliable marker of activity in inflammatory bowel disease? Am J Gastroenterol 2001; 96: 217783.
    Direct Link:
  • 45
    Gouni-Berthold I, Baumeister B, Wegel E, Berthold HK, Vetter H, Schmidt C. Neutrophil-elastase in chronic inflammatory bowel disease: a marker of disease activity? Hepatogastroenterology 1999; 46: 231520.
  • 46
    Tibble JA, Bjarnason I. Non-invasive investigations of inflammatory bowel disease. World J Gastroenterol 2001; 7: 4605.
  • 47
    Fagerhol MK, Dale I, Anderson I. Release and quantification of leukocyte derived protein (L1). Scand J Haematol 1980; 24: 3938.
  • 48
    Roseth AG, Schmidt TN, Fagerhol MK. Correlation between fecal excretion of indium 111-labeled granulocytes and calprotectin, a granulocyte marker protein in patients with inflammatory bowel disease. Scand J Gastroenterol 1999; 34: 504.
  • 49
    Tibble JA, Teahan K, Thjodleifssan B, et al. A simple method for assessing intestinal inflammation in Crohn's disease. Gut 2000; 47: 50613.
  • 50
    Roseth AG, Aadland E, Jahnsen J, et al. Assessment of disease activity in ulcerative colitis by faecal calprotectin, a novel granulocyte marker protein. Digestion 1997; 58: 17680.
  • 51
    Roseth AG, Fagerhol MK, Aadland E, Schjonsby H. Assessment of neutrophil dominating protein calprotectin in feces. A methodologic study. Scand J Gastroenterol 1992; 27: 7938.
  • 52
    Taehon K, Roseth AG, Foster R, Bjarnason I. Fecal calprotectin: a simple sensitive quantitative measure of intestinal inflammation in man (abstract). Gastroenterology 1997; 112 (Suppl.): A1103.
  • 53
    Tibble JA, Sigthorsson G, Bridger S, Fagerhol MK, Bjarnason I. Surrogate markers of intestinal inflammation are predictive of relapse in patients with inflammatory bowel disease. Gastroenterolgy 2000; 119: 1522.
  • 54
    Costa F, Mumolo MG, Ceccarelli L, et al. Calprotectin is a stronger predictive marker of relapse in ulcerative colitis than I Crohn's disease. Gut 2005; 54: 3648.
  • 55
    Kane SV, Sandborn WJ, Rufo PA, et al. Fecal lactoferrin is a sensitive and specific marker in identifying intestinal inflammation. Am J Gastroenterol 2003; 98: 130914.
    Direct Link:
  • 56
    Von Der Sluys Veer A, Biemond I, Verspaget HW, et al. Fecal parameters in the assessment of activity in inflammatory bowel disease. Scand J Gastroenterol Suppl 1999; 230: 10610.
  • 57
    Walker TR, Land ML, Cook TM, et al. Serial fecal lactoferrin measurements are useful in the interval assessment of patients with active and inactive inflammatory bowel disease. Gastroenterology 2004; 126: A215.
  • 58
    D'Inca R, Dal Pont E, Di Lee V, et al. Calprotectin and lactoferrin in the assessment of intestinal inflammation and organic disease. Int J Colorectal Dis 2006; July 13. (Epub).
  • 59
    Langhorst J, Elsenbruch S, Mueller T, et al. Comparison of 4 neutrophil-derived proteins in feces as indicators of disease activity in ulcerative colitis. Inflamm Bowel Dis 2005; 11: 108591.
  • 60
    O'Mahony S, Choudari CP, Barton JR, Walker S, Ferguson A. Gut lavage fluid proteins as markers of activity of inflammatory bowel disease. Scand J Gastroenterol 1991; 26: 9404.
  • 61
    Brignola C, Campieri M, Bazzocchi G, Farruggia G, Tragnone A, Lanfranchi GA. A laboratory index for predicting relapse in asymptomatic patients with Crohn's disease. Gastroenterology 1986; 91: 14904.
  • 62
    Reinisch W, Gasche C, Tillinger W, et al. Clinical relevance of serum interleukin-6 in Crohn's disease: single point measurements, therapy monitoring, and prediction of clinical relapse. Am J Gastroenterol 1999; 94: 215664.
    Direct Link:
  • 63
    Louis E, Belaiche J, Van Kemseke C, Schaaf N, Mahieu P, Mary JY. Soluble interleukin-2 receptor in Crohn's disease. Assessment of disease activity and prediction of relapse. Dig Dis Sci 1995; 40: 17506.
  • 64
    Bitton A, Peppercorn MA, Antonioli DA, et al. Clinical, biological, and histologic parameters as predictors of relapse in ulcerative colitis. Gastroenterology 2001; 120: 1320.
  • 65
    Yamamoto T, Umegae S, Kitagawa T, Matsumoto K. Systemic and local cytokine production in quiescent ulcerative colitis and its relationship to future relapse: a prospective pilot study. Inflamm Bowel Dis 2005; 11: 58996.